Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 12 of 12 publications.
Skip to main content
Mayer SE, Kawai A, Fuller CC, Agan AA, Rao S, Koram N, Calingaert B, Marshall J, Connolly JG, Moyneur E, Jamal-allial A, Brown J, Burk J, Chomistek A, Daniels K, Dea K, DeFor TA, Diessner B, Djibo DA, Ezzy S, Hawrusik R, Johannes CB, Kendrick K, Layton JB, Ma Q, Mai X, Mack M, Pawloski PA, Reynolds JS, Selvan M, Sharma V, Vetter J, McMahill-Walraven CN, Platt R, Gilsenan A. Interim utilization results from a post-approval safety study of Pfizer-BioNTech monovalent COVID-19 vaccine in the United States. Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.
Danysh HE, Gilsenan A, Kaye JA, Garcia de Albeniz Martinez X, Schmid R, Bartsch J, Calingaert B, Rahman S, Layton JB, Gutierrez L. Validation of algorithms to identify breast cancer and bladder cancer among patients with type 2 diabetes mellitus in United States medicare administrative claims. Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.
Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.
Danysh HE, Gilsenan A, Arana A, Pladevall-Vila M, Layton JB, Ziemiecki R, Chen H, Hunt PR, Johannes C. Validation of acute outcomes among patients with type 2 diabetes mellitus in the clinical practice research datalink. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Layton JB, Ziemiecki R, Danysh HE, Gaber C, Gilsenan A, Johannes CB. Graphical representation of an array of quantitative bias analysis scenarios for differential outcome misclassification. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Layton JB, Ziemiecki R, Danysh H, Gilsenan A, Johannes C. Graphical representation of multiple quantitative bias analysis scenarios for unmeasured confounding. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Johannes C, Layton JB, Beachler DM, Ziemiecki RM, Li L, Danysh HE, Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A. Risk of acute kidney injury in real-world use of dapagliflozin. Presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Johannes C, Layton JB, Beachler DC, Ziemiecki RM, Li L, Danysh HE, Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A. Risk of severe complications of urinary tract infection in real-world use of dapagliflozin. Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Forns J, Dudukina E, Hagg D, Szentkuti EP, Gembert K, Plana E, Gilsenan A, Horvath-Puho E, Reutfors J, Rebordosa C. Cohort study of the incidence of major cardiovascular events in new adult users of lisdexamfetamine and remote adult users of other attention-deficit/hyperactivity disorder treatments. Poster presented at the 2021 8th World Congress on ADHD Virtual Event; May 6, 2021.
Ruigomez A, Plana E, Gilsenan A, Fortuny J, Cainzos-Achirica M, Flynn RWV, MacDonald TM, Garcia-Rodriguez L, Ziemiecki R, Andrews EB. Identification and validation of major cardiovascular events in the United Kingdom data sources included in a multi-database post-authorization safety study of prucalopride. Drug Saf. 2021 May;44(5):541-51. doi: 10.1007/s40264-021-01044-4
Oppenheimer J, Slade DJ, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Lima R, Molfino NA, Averell CM. Real-world evidence: patient views on asthma in respiratory specialist clinics in America. Ann Allergy Asthma Immunol. 2021 Apr;126(4):385-93. doi: 10.1016/j.anai.2020.12.015
Arana A, Margulis AV, Varas-Lorenzo C, Bui CL, Gilsenan A, McQuay LJ, Reynolds M, Rebordosa C, Franks B, de Vogel S, Appenteng K, Perez-Gutthann S. Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150